Halting the Vicious Cycle of Atopic Dermatitis: Empowered by Scientific Understanding

The progress in our understanding of atopic dermatitis (AD) (atopic eczema) in the last 10 years has been remarkable. Nearly half of the scientific papers ever published on AD have been written in the last 10 years. This contribution of knowledge, in parallel with technological and pharmaceutical progress, has transformed our ability to treat some of the most severe forms of AD. Notably, we have seen the advent of biologics such as the anti –IL-4 receptor biologic dupilumab (Simpson et al, 2016), 2 anti–IL-13 agents (tralokinumab [Wollenberg et al, 2021] and lebrikizumab [Silverberg et al, 2023]), and small-molecular Jak inhibitors (the Jak1 inhibitors upadacitinib [Guttman-Yassky et al, 2021] and abrocitinib [Simpson et al, 2 020] and the Jak1/Jak2 inhibitor baricitinib [Zhou et al, 2021]).
Source: Journal of Investigative Dermatology - Category: Dermatology Authors: Tags: Editorial Source Type: research